Neutrolis Licenses University of Illinois Chicago Patent to Advance Topical Dry Eye Disease Therapy Targeting NETs CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and...

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and...